IRD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Opus Genetics Inc (IRD) is a good buy for a beginner investor with a long-term horizon and $50,000-$100,000 available for investment. The stock shows strong positive momentum, favorable analyst ratings, significant hedge fund interest, and a promising pipeline in gene therapy for inherited retinal diseases. Despite weak financial performance in the latest quarter, the company's recent financing agreement and potential catalysts in mid-2026 make it an attractive long-term investment opportunity.
The stock is in a bullish trend with MACD above 0 and positively expanding, RSI indicating overbought conditions at 81.692, and moving averages showing a bullish alignment (SMA_5 > SMA_20 > SMA_200). The price is above key resistance levels, suggesting strong upward momentum.
Hedge funds are heavily buying, with a 2167.49% increase in buying activity last quarter.
Recent financing agreement with Oberland Capital for $155 million extends cash runway into 2029 and supports pivotal studies for gene therapy programs.
Positive analyst ratings and price targets ranging from $10 to $15, with potential catalysts in mid-2026 from Phase 1 trial results of OPGx-BEST
Strong clinical data in inherited eye diseases, with a significant market opportunity in BEST1 and LCA5 programs.
Financial performance in Q4 2025 showed declining revenue (-10.16% YoY), net income (-52.97% YoY), and EPS (-81.90% YoY).
RSI indicates overbought conditions, suggesting a potential short-term pullback.
The company's Q4 2025 financials showed a revenue decline to $3,865,000 (-10.16% YoY), net income dropped to -$16,523,000 (-52.97% YoY), and EPS fell to -0.21 (-81.90% YoY). However, gross margin remained stable at 100%.
Analysts are highly bullish on Opus Genetics, with ratings of Overweight and Outperform from firms like Cantor Fitzgerald, Oppenheimer, Wedbush, and BTIG. Price targets range from $10 to $15, with potential upside driven by clinical trial results and a significant market opportunity in gene therapy for inherited retinal diseases.
